There are no pitches that meet the Top Bull criteria. Explain
If this upsets you, start recommending pitches below!
BioPharm Asia is a fairly new (1 year) US uplist that started about $5.00 per share, but spent the last few months around $1, before rising back up above $4 this week on two events. One good earning and filing of "late" SEC reports that gave it the… More